Ustekinumab and nutrition before Crohn's surgery
Part of Digestive system clinical trials.
This trial tests if combining a drug called ustekinumab with a special liquid diet (semi-exclusive enteral nutrition) is as effective as using only the liquid diet to improve outcomes before Crohn's surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Crohn's disease and are scheduled for bowel surgery.
- You are between 18 and 65 years old.
- Your Crohn's symptoms are active (CDAI score above 150).
- You have not used ustekinumab before and are willing to stop other treatments that didn't work.
- If you have an abscess in your belly, it must be treated and cleared before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if checking a stool marker (fecal calprotectin) early after surgery can guide treatment with ustekinumab to prevent Crohn's disease from coming back. It's for people who had certain bowel surgery and have at least one risk factor for recurrence.
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
This study tests a new oral treatment called EXL01 to see if it can prevent Crohn's disease from coming back after surgery to remove part of the small and large intestine. It may be an option if you are not planning to use strong immune-suppressing drugs (except anti-TNF) in the next 6 months.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This trial tests whether a special liquid-only diet (exclusive enteral nutrition) can help people with active Crohn's disease, including those with complications like fistulas or narrowing of the intestine. It aims to improve nutrition and reduce disease activity without medication.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.